Everolimus May Shrink Rare Type Of Benign Kidney Tumor.

MedPage Today  (2/7, Phend) reports, "The cancer drug everolimus (Afinitor) appears to shrink a rare type of benign kidney tumor often seen with tuberous sclerosis," according to research presented at the Genitourinary Cancers Symposium. Investigators found that "daily oral treatment shrank 42% of angiomyolipomas to at least half their original volume, whereas no placebo-treated patients saw any tumor regression (P<0.0001)." The researchers also found that "the toxicity was low, without any excess in infections, in the randomized EXIST-2 trial."